The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: A double-blind, placebo-controlled study

被引：125
|
作者：
Snow, BJ [1 ]
Macdonald, L [1 ]
Mcauley, D [1 ]
Wallis, W [1 ]
机构：
[1] Auckland Hosp, Dept Neurol, Auckland, New Zealand
来源：
CLINICAL NEUROPHARMACOLOGY | 2000年 / 23卷 / 02期
关键词：
amantadine; Parkinson's disease; dyskinesia;
D O I：
10.1097/00002826-200003000-00004
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
We performed a double-blind, placebo-controlled, crossover study to assess the effect of amantadine versus placebo on levodopa-induced dyskinesias in Parkinson's disease. We found a 24% reduction in the total dyskinesia score after amantadine administration (p = 0.004). This improvement was achievement without any influence on the severity of "on" period parkinsonism. The results confirm that amantadine reduces levodopa dyskinesias and support the hypothesis that dyskinesias can be reduced by blockade of excitatory pathways in the basal ganglia.
引用
收藏
页码：82 / 85
页数：4
相关论文
共 50 条
  • [21] Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo controlled trial
    Goetz, C. G.
    Damier, P.
    Hicking, C.
    Lasko, E.
    Muller, T.
    Olanow, C. W.
    Rascol, O.
    Russ, H.
    [J]. MOVEMENT DISORDERS, 2006, 21 : S606 - S607
  • [22] Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease
    Olanow, CW
    Kieburtz, K
    Stern, M
    Watts, R
    Langston, MW
    Guarnieri, M
    Hubble, J
    Atchison, P
    Bartel, D
    Bernik, C
    Bertoni, J
    Bharucha, K
    Blady, D
    Brandabur, M
    Chippendale, T
    Cleeremans, B
    Comella, C
    Counihan, T
    Durso, R
    Edelsohn, L
    Ellis, J
    Elmer, L
    Evans, B
    Forchetti, C
    Freeman, A
    Galvez-Jimenez, N
    Gazda, S
    Gollomp, S
    Gracies, J
    Greeley, D
    Harris, J
    Hauser, R
    Hershey, L
    Hoehn, M
    Hoffsteter, M
    Hormes, J
    Hubble, J
    Hutton, T
    Jankovic, J
    Kaminow, L
    Kassicieh, D
    Kirzinger, S
    Kishner, R
    Klapper, J
    Knox, C
    Koller, W
    Leonard, H
    Levin, K
    LeWitt, P
    Marcadis, A
    [J]. ARCHIVES OF NEUROLOGY, 2004, 61 (10) : 1563 - 1568
  • [23] Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments
    Bargiotas, Panagiotis
    Konitsiotis, Spyridon
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2013, 9 : 1605 - 1617
  • [24] Risk factors for levodopa-induced dyskinesias in Parkinson's disease
    Grandas, F
    Galiano, ML
    Tabernero, C
    [J]. JOURNAL OF NEUROLOGY, 1999, 246 (12) : 1127 - 1133
  • [25] Levetiracetam for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease
    Stathis, P.
    Konitsiotis, S.
    Tagaris, G.
    Peterson, D.
    [J]. MOVEMENT DISORDERS, 2011, 26 (02) : 264 - 270
  • [26] Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease
    Metman, LV
    Del Dotto, P
    Natté, R
    van den Munckhof, P
    Chase, TN
    [J]. NEUROLOGY, 1998, 51 (01) : 203 - 206
  • [27] Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease
    Merims, D
    Ziv, I
    Djaldetti, R
    Melamed, E
    [J]. LANCET, 1999, 353 (9166): : 1764 - 1765
  • [28] Accelerometric assessment of levodopa-induced dyskinesias in Parkinson's disease
    Hoff, JI
    vander Plas, AA
    Wagemans, EAH
    van Hilten, JJ
    [J]. MOVEMENT DISORDERS, 2001, 16 (01) : 58 - 61
  • [29] Risk factors for levodopa-induced dyskinesias in Parkinson’s disease
    F. Grandas
    Maria Luisa Galiano
    Cesar Tabernero
    [J]. Journal of Neurology, 1999, 246 : 1127 - 1133
  • [30] Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?
    Calabresi, Paolo
    Standaert, David G.
    [J]. NEUROBIOLOGY OF DISEASE, 2019, 132
12345